Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln

Xspray Pharma publ AB

28/04/2026 07:12

April 28 (Reuters) - Xspray Pharma publ AB XSPRAY.ST:

Q1 PRETAX PROFIT SEK -35.38 MILLION

Q1 ADJUSTED FREE CASH FLOW SEK -30.676 MILLION

Q1 REVENUE SEK 0

Q1 ADJUSTED EPS SEK -0.85

XSPRAY'S PLAN TO LAUNCH IN U.S. DURING SECOND HALF OF 2026.

WELL PREPARED FOR A DUAL LAUNCH OF DASYNOC® AND NILOPKI® IN AUTUMN OF 2026.

Source text: ID:nMFNb1mrH0

Further company coverage: XSPRAY.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))